A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFRI-Amplified Squamous Non-Small Cell Lung Cancer

Trial Profile

A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFRI-Amplified Squamous Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2016

At a glance

  • Drugs AZD 4547 (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2014 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 04 Feb 2014 Status changed from not yet recruiting to suspended as reported by ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top